Active	Status	Sponsor type	Region	Phase	Filter
3 Active 1 Inactive 4 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   - « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
FG-3246 / Fortis Therap, FibroGen
NCT06842498: A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)	Not yet recruiting	2	75	US	FG-3246, FOR46	FibroGen	Metastatic Castration-Resistant Prostate Cancer	09/27	09/27
NCT05011188: FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer	Recruiting	1/2	36	US	FOR46, Antibody-Drug Conjugate (ADC), anti-CD46 antibody conjugate, Enzalutamide, XTANDI, Pegfilgrastim, G-CSF, Blood Samples, Blood Specimen, Biospecimen	Rahul Aggarwal, Fortis Therapeutics, Inc., FibroGen	Metastatic Castration-resistant Prostate Cancer, Prostate Cancer	03/27	03/27
NCT03575819: A Phase 1 Study of FOR46 in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)	Completed	1	56	US	FOR46	Fortis Therapeutics, Inc.	Prostate Cancer Metastatic	11/23	11/23

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
FG-3246 / Fortis Therap, FibroGen
NCT06842498: A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)	Not yet recruiting	2	75	US	FG-3246, FOR46	FibroGen	Metastatic Castration-Resistant Prostate Cancer	09/27	09/27
NCT05011188: FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer	Recruiting	1/2	36	US	FOR46, Antibody-Drug Conjugate (ADC), anti-CD46 antibody conjugate, Enzalutamide, XTANDI, Pegfilgrastim, G-CSF, Blood Samples, Blood Specimen, Biospecimen	Rahul Aggarwal, Fortis Therapeutics, Inc., FibroGen	Metastatic Castration-resistant Prostate Cancer, Prostate Cancer	03/27	03/27
NCT03575819: A Phase 1 Study of FOR46 in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)	Completed	1	56	US	FOR46	Fortis Therapeutics, Inc.	Prostate Cancer Metastatic	11/23	11/23